September 2003
Worldwide Biotech;Sep2003, Vol. 15 Issue 9, p6
Trade Publication
Reports on the ability of CYC202 (R-roscovitine), a cyclin-dependent kinases inhibitor product from Cyclacel Ltd., to induce cancer cell suicide or apoptosis in patients receiving the drug.


Related Articles

  • CYCLACEL REPORTS PROGRESS WITH 2ND GENERATION CDK INHIBITOR.  // Worldwide Biotech;Jul2003, Vol. 15 Issue 7, p4 

    Focuses on the cyclin dependent kinase inhibitors for the genes-to-drugs CYC400 rational drug design program of the biopharmaceutical firm Cyclacel Ltd. in Great Britain.

  • Align Acquisition Pads Cyclacel's Resource Base. Young, Donna // BioWorld Today;10/9/2007, Vol. 18 Issue 196, p1 

    This article reports on the acquisition of Align Pharmaceuticals LLC by Cyclacel Pharmaceuticals Inc. in a deal worth up to $3.8 million in cash. Aside from the cash, the deal also involves stock paid to Align Holding LLC. Cyclacel Pharmaceuticals is involved in the development of products for...

  • Cyclacel to speed up Altana drug development.  // PharmaWatch: Cancer;May 2005, Vol. 4 Issue 5, p15 

    Reports that Cyclacel Group PLC and Altana Pharma AG have signed a research collaboration agreement to identify molecular agents of experimental cancer drugs. Terms of the agreement; Comments of the chief scientist of Cyclacel's Polgen division, David Glover regarding on the discovery of...

  • Cyclacel Announces Clinical Trials For Inflammatory Disease Drug.  // Drug Discovery & Development;Jun2002, Vol. 5 Issue 6, p25 

    Reports on British-based Cyclacel's plan to investigate in clinical trials the potential use of its lead drug, CYC202, in the treatment of glomerulonephritis (GN), a group of inflammatory diseases of the kidney. Phases of clinical trials completed.

  • Business to Business.  // BioPharm International;Jan2004, Vol. 17 Issue 1, p14 

    Reports global developments related to pharmaceutical industry as of January 2004. Sale of the generic drug business RPG Aventis by Aventis to Ranbaxy Laboratories; Agreement between Scynexis Europe Ltd. and GeneCare Research Institute Co. Ltd.; Acquisition of rights to an anticancer treatment...

  • Cyclacel Cutting 28 Staffers, Will Focus on Sapacitabine. Moran, Nuala // BioWorld International;9/24/2008, Vol. 13 Issue 39, p1 

    The article reports on the decision of Cyclacel Inc. to reduce its British research and development operations and close its facility in Cambridge as part of a restructuring effort. A total of 28 staff members will leave the company, with 17 in the research base. President Spiro Rombotis says...

  • Cyclacel acquires novel anticancer drug from Lorus Therapeutics.  // PharmaWatch: Biotechnology;November 2003, Vol. 2 Issue 11, p22 

    Reports on the acquisition of the anticancer drug CYC381 from the biotechnology firm Lorus Therapeutics Inc. by Cyclacel Ltd. Ability of the drug to arrest cancer cells; Terms of the agreement; Payment received by Lorus from the agreement.

  • Licensing News Headlines September 15, 2003 - October 14, 2003.  // PharmaWatch: Biotechnology;November 2003, Vol. 2 Issue 11, p21 

    Reports developments related to contracts in the biotechnology sector from September 2003 to October 2003. Collaboration between Acambis PLC and George Mason University; Termination of the partnership between AstraZeneca PLC and NicOx SA; Acquisition of the anticancer drug from Lorus...

  • Biotech Beckons in Bonny Scotland. Jack, Lorna // Bio-IT World;Oct2005, Vol. 4 Issue 10, p46 

    Focuses on the network of global partnerships and collaborations that contributed to the success of the life science sector in Scotland. Opportunities available for collaboration with Scottish biomedical innovators that motivate U.S. biotechnology firms to invest in the industry; Role of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics